China Pharma Holdings ROE 2012-2026 | CPHI
Current and historical return on equity (ROE) values for China Pharma Holdings (CPHI) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| China Pharma Holdings ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-03-31 | $0.00B | $0.02B | -21.62% |
| 2025-12-31 | $0.00B | $0.01B | -36.36% |
| 2025-09-30 | $0.00B | $0.01B | -55.17% |
| 2025-06-30 | $0.00B | $0.01B | -57.14% |
| 2025-03-31 | $0.00B | $0.01B | -55.17% |
| 2024-12-31 | $0.00B | $0.01B | -53.33% |
| 2024-09-30 | $0.00B | $0.01B | -55.17% |
| 2024-06-30 | $0.00B | $0.01B | -57.14% |
| 2024-03-31 | $0.00B | $0.01B | -64.00% |
| 2023-12-31 | $0.00B | $0.01B | -54.55% |
| 2023-09-30 | $0.00B | $0.01B | -63.16% |
| 2023-06-30 | $0.00B | $0.00B | -75.00% |
| 2023-03-31 | $0.00B | $0.00B | -75.00% |
| 2022-12-31 | $0.00B | $0.00B | -100.00% |
| 2022-09-30 | $0.00B | $0.01B | -88.89% |
| 2022-06-30 | $0.00B | $0.01B | -72.73% |
| 2022-03-31 | $0.00B | $0.01B | -64.00% |
| 2021-12-31 | $0.00B | $0.01B | -59.26% |
| 2021-09-30 | $0.00B | $0.01B | -55.17% |
| 2021-06-30 | $0.00B | $0.01B | -53.33% |
| 2021-03-31 | $0.00B | $0.01B | -38.71% |
| 2020-12-31 | $0.00B | $0.01B | -37.50% |
| 2020-09-30 | $-0.02B | $0.01B | -254.55% |
| 2020-06-30 | $-0.02B | $0.01B | -161.54% |
| 2020-03-31 | $-0.02B | $0.02B | -120.55% |
| 2019-12-31 | $-0.02B | $0.02B | -87.50% |
| 2019-09-30 | $-0.01B | $0.03B | -34.19% |
| 2019-06-30 | $-0.01B | $0.03B | -34.38% |
| 2019-03-31 | $-0.01B | $0.04B | -31.43% |
| 2018-12-31 | $-0.01B | $0.04B | -28.76% |
| 2018-09-30 | $-0.02B | $0.04B | -40.96% |
| 2018-06-30 | $-0.02B | $0.05B | -36.76% |
| 2018-03-31 | $-0.02B | $0.05B | -35.82% |
| 2017-12-31 | $-0.02B | $0.05B | -35.35% |
| 2017-09-30 | $-0.01B | $0.06B | -13.85% |
| 2017-06-30 | $-0.01B | $0.06B | -13.39% |
| 2017-03-31 | $-0.01B | $0.06B | -12.85% |
| 2016-12-31 | $-0.01B | $0.07B | -13.69% |
| 2016-09-30 | $-0.02B | $0.07B | -30.32% |
| 2016-06-30 | $-0.02B | $0.07B | -21.84% |
| 2016-03-31 | $-0.01B | $0.08B | -16.20% |
| 2015-12-31 | $-0.02B | $0.08B | -17.80% |
| 2015-09-30 | $-0.02B | $0.09B | -24.65% |
| 2015-06-30 | $-0.03B | $0.10B | -31.71% |
| 2015-03-31 | $-0.04B | $0.10B | -39.33% |
| 2014-12-31 | $-0.04B | $0.12B | -34.06% |
| 2014-09-30 | $-0.03B | $0.13B | -21.69% |
| 2014-06-30 | $-0.02B | $0.13B | -17.49% |
| 2014-03-31 | $-0.02B | $0.14B | -13.11% |
| 2013-12-31 | $-0.02B | $0.14B | -13.40% |
| 2013-09-30 | $-0.01B | $0.15B | -6.86% |
| 2013-06-30 | $-0.01B | $0.15B | -4.75% |
| 2013-03-31 | $0.00B | $0.15B | -0.67% |
| 2012-12-31 | $0.01B | $0.15B | 3.38% |
| 2012-09-30 | $0.01B | $0.15B | 6.84% |
| 2012-06-30 | $0.01B | $0.14B | 9.76% |
| 2012-03-31 | $0.02B | $0.14B | 12.21% |
| 2011-12-31 | $0.02B | $0.13B | 14.21% |
| 2011-09-30 | $0.02B | $0.13B | 17.22% |
| 2011-06-30 | $0.02B | $0.12B | 19.01% |
| 2011-03-31 | $0.02B | $0.11B | 21.05% |
| 2010-12-31 | $0.02B | $0.11B | 22.38% |
| 2010-09-30 | $0.02B | $0.10B | 20.05% |
| 2010-06-30 | $0.02B | $0.09B | 22.52% |
| 2010-03-31 | $0.02B | $0.09B | 21.84% |
| 2009-12-31 | $0.02B | $0.08B | 22.15% |
| 2009-09-30 | $0.02B | $0.08B | 26.06% |
| 2009-06-30 | $0.02B | $0.07B | 23.78% |
| 2009-03-31 | $0.02B | $0.07B | 25.37% |
| 2008-12-31 | $0.02B | $0.06B | 28.33% |
| 2008-09-30 | $0.02B | $0.05B | 30.48% |
| 2008-06-30 | $0.02B | $0.05B | 33.15% |
| 2008-03-31 | $0.01B | $0.04B | 36.84% |
| 2007-12-31 | $0.01B | $0.03B | 36.09% |
| 2007-09-30 | $0.01B | $0.03B | 38.60% |
| 2007-06-30 | $0.01B | $0.02B | 41.67% |
| 2007-03-31 | $0.01B | $0.02B | 45.00% |
| 2006-12-31 | $0.01B | $0.02B | 54.55% |
| 2006-09-30 | $0.01B | $0.01B | 63.16% |
| 2006-06-30 | $0.01B | $0.01B | 71.11% |
| 2006-03-31 | $0.01B | $0.01B | 80.00% |
| 2005-12-31 | $0.00B | $0.00B | 94.12% |
| 2005-09-30 | $0.00B | $0.00B | 80.00% |
| 2005-06-30 | $0.00B | 0 | 0.00% |
| 2004-12-31 | $0.00B | 0 | 0.00% |
| 2004-09-30 | $0.00B | 0 | 0.00% |
| 2003-12-31 | $0.00B | -0 | 0.00% |
| 2003-09-30 | $0.00B | $0.00B | 0.00% |
| 2002-12-31 | $0.00B | $0.00B | 0.00% |
| 2002-09-30 | $0.00B | -0 | 0.00% |
| 2002-03-31 | $0.00B | 0 | 0.00% |
| 2001-12-31 | $0.00B | 0 | 0.00% |
| 2001-09-30 | $0.00B | 0 | 0.00% |
| 2001-06-30 | $0.00B | 0 | 0.00% |
| 2001-03-31 | $0.00B | 0 | 0.00% |
| 2000-12-31 | $0.00B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |